Centre Hospitalier Universitaire De Nice
- Address
- lock Available on a paid plan
Nervous System Diseases
At Centre Hospitalier Universitaire De Nice, the Neurology department is involved in research on Nervous System Diseases, with a strong focus on conditions such as multiple sclerosis, Parkinson’s disease, generalized myasthenia gravis, and facioscapulohumeral muscular dystrophy. These studies are designed to assess new treatment options, compare established therapies, and better understand how to slow disease progression and improve daily function.
- Testing therapies for multiple sclerosis to reduce disease activity and support long-term control
- Evaluating treatment approaches for Parkinson’s disease to delay motor decline
- Studying new options for myasthenia gravis and other neuromuscular disorders
This area reflects a broad effort to improve both symptom management and long-term outcomes for people living with complex neurological conditions.
Cardiovascular and Stroke Research
The site is also active in Cardiovascular Diseases, including studies in acute coronary syndrome, atherosclerotic cardiovascular disease, atrial fibrillation, and stroke prevention. Research here aims to test whether new treatments can lower the risk of heart attack, stroke, and other major cardiovascular events while balancing safety concerns such as bleeding risk.
- Assessing therapies to reduce recurrent events after acute coronary syndrome
- Improving prevention of ischemic stroke in high-risk patients
- Comparing treatment strategies for atrial fibrillation to prevent stroke or systemic embolism
These studies support better prevention and long-term management of serious vascular disease in patients at elevated risk.
Respiratory and Interstitial Lung Disease
Clinical trials at this hospital in Nice include important work in Respiratory Tract Diseases, especially idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, interstitial lung disease, bronchiectasis, and asthma. The main goal is to evaluate therapies that may improve lung function, reduce flare-ups, and slow worsening of chronic lung disorders.
- Testing treatments for pulmonary fibrosis and related scarring conditions
- Studying care options for bronchiectasis and early airway infections
- Evaluating new approaches for severe asthma in children and adolescents
This research area is centered on finding better ways to preserve breathing capacity and quality of life in patients with chronic respiratory disease.
Rheumatology and Immune-Mediated Disease
The research portfolio also covers Immune System Diseases and Musculoskeletal Diseases, with studies in rheumatoid arthritis, dermatomyositis, and systemic sclerosis-associated interstitial lung disease. These trials are focused on comparing treatment strategies, reducing inflammation, and improving symptoms and physical function in autoimmune conditions.
- Comparing therapies for rheumatoid arthritis to improve remission rates
- Exploring new treatments for dermatomyositis and related muscle inflammation
- Assessing immune-targeted approaches in systemic sclerosis-related lung involvement
This work highlights the site’s role in advancing care for chronic inflammatory diseases that can affect both joints and internal organs.
Other Specialized Clinical Research
Beyond the major disease groups, Centre Hospitalier Universitaire De Nice contributes to studies in Analytical, Diagnostic and Therapeutic Techniques and Equipment, including research aimed at improving procedures and treatment support. One example is work on kidney stone management, where trials assess whether new supportive strategies can improve stone clearance and recovery after treatment.
- Improving outcomes in kidney stone treatment
- Supporting better procedural results in urological care
- Evaluating practical ways to enhance treatment effectiveness across specialized care settings
This mixed research activity shows a broad commitment to refining patient care across several clinical fields, not only disease treatment but also the tools and approaches used to deliver it.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 15 therapeutic areas and 15 of 113 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 112 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 34 by active trials.
lock +33 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Universitaire De Nice
lock Showing 1 of 67 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA) | AstraZeneca AB | Phase III | Not Recruiting | Jun 2023 | — |
IMP list
lock Showing 1 of 113 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 4 | Unknown | 2022-09-15 | 2026-04-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
